ArticleNeuroImage2026
Detecting early brain susceptibility changes before demyelination in cuprizone mouse model using quantitative susceptibility mapping (QSM).
Article in NeuroImage, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Multiple sclerosis (MS) is a neurological disease that affects the central nervous system through demyelination and inflammation. Animal model, including the cuprizone (CPZ) model, provides a robust platform for studying demyelination and remyelination in MS. While conventional MRI techniques are sensitive to myelin changes, quantitative susceptibility mapping (QSM) offers additional advantages by capturing both myelin- and iron-related pathology. In this study, we performed longitudinal whole-brain multimodal magnetic resonance imaging (MRI), including T2-weighted imaging, magnetization transfer imaging, and QSM, in CPZ-treated mice across multiple stages covering pre-demyelination, acute demyelination, chronic demyelination, and remyelination. Regional analyses focused on the corpus callosum (CC) and anterior commissure (AC), complemented by histological validation. All three MRI modalities detected demyelination, characterized by increased T2 signal, decreased magnetization transfer ratio (MTR), and increased susceptibility, with partial recovery during remyelination. QSM demonstrated unique sensitivity by identifying susceptibility decreases at week 2, before apparent demyelination, corresponding to early oligodendrocyte dysfunction. Regional heterogeneity was observed, with the CC showing rapid alterations during acute demyelination and the AC exhibiting steadier changes across acute and chronic phases. These results establish QSM as a sensitive imaging biomarker capable of detecting early MS pathology and tracking dynamic changes in oligodendrocytes. By complementing conventional MRI techniques, QSM enhances the characterization of white matter injury in the CPZ model and holds translational potential for monitoring disease progression and therapeutic response in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.